EML4-ALK and EGFR mutation status and survival analysis in Uygur with stageⅣNSCLC
10.11958/58911
- VernacularTitle:Ⅳ期维吾尔族NSCLC患者EML4-ALK、EGFR基因突变状态及生存分析
- Author:
Qiang WANG
;
Qiao ZHANG
;
Yanzhen CAO
;
Jie TAO
;
Li SHAN
- Publication Type:Journal Article
- Keywords:
carcinoma;
non-small-cell lung;
receptor;
epidermal growth factor;
mutation;
UYGUR NATIONALITY;
non-small cell lung cancer;
EML4-ALK;
survival analysis
- From:
Tianjin Medical Journal
2016;44(2):200-204
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the relationship between the echinoderm microtubule associated protein like 4-anaplastic lymphoma kinase (EML4-ALK) and epithelial growth factor receptor (EGFR) mutation status and overall survival (OS) in Uygur patients with stageⅣnon-small cell lung cancer (NSCLC) who did not accept tyrosine kinase inhibitor treat-ment. Methods Totally 97 tissue samples were collected from Uygur patients with stageⅣNSCLC who did not accept tyro-sine kinase inhibitor treatment. EML4-ALK fusion gene and EGFR mutation status were detected by using FISH and ARMS methods. The survival rates were analysed. Results In 97 tissue samples, EML4-ALK fusion genes were found in 6 (6.2%) samples, EGFR mutations were found in 26 (26.8%) samples. The survival analysis showed that there was no significant dif-ference in OS between EML4-ALK fusion gene group and no EML4-ALK fusion gene group (P=0.941). There was no signifi-cant difference in OS between EGFR mutation group and wild-type EGFR group (P=0.607). The values of median OS were 17.7 months, 17.3 months and 16.2 months for EGFR mutant group, EML4-ALK positive group and EML4-ALK negative+EGFR wild-type group, and thre was no significant difference between them (P=0.915). Conclusion Excluding the thera-peutic influence in TKIs, EML4-ALK fusion gene and EGFR mutation status of tumor tissue can not be used as an indepen-dent factor in assessing the prognosis in Uygur patients with stageⅣNSCLC.
